{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T17:12:04Z","timestamp":1794244324455,"version":"4.9.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T00:00:00Z","timestamp":1728518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T00:00:00Z","timestamp":1728518400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81920108020 and 82325028"],"award-info":[{"award-number":["81920108020 and 82325028"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["Z220011 and Z220014"],"award-info":[{"award-number":["Z220011 and Z220014"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005090","name":"Beijing Nova Program","doi-asserted-by":"publisher","award":["20220484182"],"award-info":[{"award-number":["20220484182"]}],"id":[{"id":"10.13039\/501100005090","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-024-53197-2","type":"journal-article","created":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T14:02:02Z","timestamp":1728568922000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["68Ga-grazytracer PET for noninvasive assessment of response to immunotherapy in solid tumors and lymphomas: a phase 1\/2 clinical trial"],"prefix":"10.1038","volume":"15","author":[{"given":"Xiuling","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoyi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2008-3793","authenticated-orcid":false,"given":"Zongchao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6590-011X","authenticated-orcid":false,"given":"Xiangxi","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufei","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8336-5552","authenticated-orcid":false,"given":"Wenqing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2084-5193","authenticated-orcid":false,"given":"Zhi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8718-8154","authenticated-orcid":false,"given":"Zhaofei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8619-7550","authenticated-orcid":false,"given":"Nan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,10]]},"reference":[{"key":"53197_CR1","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","volume":"21","author":"A Marabelle","year":"2020","unstructured":"Marabelle, A. et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 21, 1353\u20131365 (2020).","journal-title":"Lancet Oncol."},{"key":"53197_CR2","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.cell.2017.07.025","volume":"170","author":"A Jimenez-Sanchez","year":"2017","unstructured":"Jimenez-Sanchez, A. et al. Heterogeneous tumor-immune microenvironments among differentially growing metastases in an ovarian cancer patient. Cell 170, 927\u2013938.e20 (2017).","journal-title":"Cell"},{"key":"53197_CR3","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228\u2013247 (2009).","journal-title":"Eur. J. Cancer"},{"key":"53197_CR4","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1080\/10428190601078126","volume":"48","author":"S Assouline","year":"2007","unstructured":"Assouline, S. et al. Development of adapted RECIST criteria to assess response in lymphoma and their comparison to the International Workshop Criteria. Leuk. Lymphoma 48, 513\u2013520 (2007).","journal-title":"Leuk. Lymphoma"},{"key":"53197_CR5","doi-asserted-by":"publisher","first-page":"3541","DOI":"10.1200\/JCO.2015.61.6870","volume":"33","author":"VL Chiou","year":"2015","unstructured":"Chiou, V. L. & Burotto, M. Pseudoprogression and immune-related response in solid tumors. J. Clin. Oncol. 33, 3541\u20133543 (2015).","journal-title":"J. Clin. Oncol."},{"key":"53197_CR6","doi-asserted-by":"publisher","first-page":"355ra116","DOI":"10.1126\/scitranslmed.aaf8621","volume":"8","author":"CJ Turtle","year":"2016","unstructured":"Turtle, C. J. et al. Immunotherapy of non-Hodgkin\u2019s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Sci. Transl. Med. 8, 355ra116 (2016).","journal-title":"Sci. Transl. Med."},{"key":"53197_CR7","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","volume":"18","author":"L Seymour","year":"2017","unstructured":"Seymour, L. et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 18, e143\u2013e152 (2017).","journal-title":"Lancet Oncol."},{"key":"53197_CR8","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1093\/annonc\/mdx168","volume":"28","author":"J Le Lay","year":"2017","unstructured":"Le Lay, J., Jarraya, H., Lebellec, L. & Penel, N. irRECIST and iRECIST: the devil is in the details. Ann. Oncol. 28, 1676\u20131678 (2017).","journal-title":"Ann. Oncol."},{"key":"53197_CR9","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1182\/blood-2016-05-718528","volume":"128","author":"BD Cheson","year":"2016","unstructured":"Cheson, B. D. et al. Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy. Blood 128, 2489\u20132496 (2016).","journal-title":"Blood"},{"key":"53197_CR10","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1148\/radiol.2020192056","volume":"295","author":"FZ Mokrane","year":"2020","unstructured":"Mokrane, F. Z. et al. Performance of CT compared with 18F-FDG PET in predicting the efficacy of nivolumab in relapsed or refractory hodgkin lymphoma. Radiology 295, 651\u2013661 (2020).","journal-title":"Radiology"},{"key":"53197_CR11","doi-asserted-by":"publisher","first-page":"122s","DOI":"10.2967\/jnumed.108.057307","volume":"50","author":"RL Wahl","year":"2009","unstructured":"Wahl, R. L., Jacene, H., Kasamon, Y. & Lodge, M. A. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J. Nucl. Med. 50, 122s\u2013150s (2009).","journal-title":"J. Nucl. Med."},{"key":"53197_CR12","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1148\/rg.2018180060","volume":"38","author":"A Kandathil","year":"2018","unstructured":"Kandathil, A., Kay, F. U., Butt, Y. M., Wachsmann, J. W. & Subramaniam, R. M. Role of FDG PET\/CT in the eighth edition of TNM staging of non-small cell lung cancer. Radiographics 38, 2134\u20132149 (2018).","journal-title":"Radiographics"},{"key":"53197_CR13","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson, B. D. et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J. Clin. Oncol. 32, 3059\u20133068 (2014).","journal-title":"J. Clin. Oncol."},{"key":"53197_CR14","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.ejim.2013.06.012","volume":"25","author":"L Tagliabue","year":"2014","unstructured":"Tagliabue, L. & Del Sole, A. Appropriate use of positron emission tomography with [18F]fluorodeoxyglucose for staging of oncology patients. Eur. J. Intern. Med. 25, 6\u201311 (2014).","journal-title":"Eur. J. Intern. Med."},{"key":"53197_CR15","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.ejca.2015.11.018","volume":"55","author":"VR Bollineni","year":"2016","unstructured":"Bollineni, V. R., Kramer, G. M., Jansma, E. P., Liu, Y. & Oyen, W. J. A systematic review on [18F]FLT-PET uptake as a measure of treatment response in cancer patients. Eur. J. Cancer 55, 81\u201397 (2016).","journal-title":"Eur. J. Cancer"},{"key":"53197_CR16","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.annonc.2021.10.213","volume":"33","author":"IC Kok","year":"2022","unstructured":"Kok, I. C. et al. 89Zr-pembrolizumab imaging as a non-invasive approach to assess clinical response to PD-1 blockade in cancer. Ann. Oncol. 33, 80\u201388 (2022).","journal-title":"Ann. Oncol."},{"key":"53197_CR17","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1038\/s41591-018-0255-8","volume":"24","author":"F Bensch","year":"2018","unstructured":"Bensch, F. et al. 89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer. Nat. Med. 24, 1852\u20131858 (2018).","journal-title":"Nat. Med."},{"key":"53197_CR18","doi-asserted-by":"publisher","first-page":"536","DOI":"10.2967\/jnumed.121.262045","volume":"63","author":"X Zhou","year":"2022","unstructured":"Zhou, X. et al. First-in-humans evaluation of a PD-L1-binding peptide PET radiotracer in non-small cell lung cancer patients. J. Nucl. Med. 63, 536\u2013542 (2022).","journal-title":"J. Nucl. Med."},{"key":"53197_CR19","doi-asserted-by":"publisher","first-page":"499","DOI":"10.2217\/imt-2016-0150","volume":"9","author":"PN Aguiar Jr.","year":"2017","unstructured":"Aguiar, P. N. Jr., De Mello, R. A., Hall, P., Tadokoro, H. & Lima Lopes, G. PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data. Immunotherapy 9, 499\u2013506 (2017).","journal-title":"Immunotherapy"},{"key":"53197_CR20","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1186\/s40425-019-0768-9","volume":"7","author":"AA Davis","year":"2019","unstructured":"Davis, A. A. & Patel, V. G. The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors. J. Immunother. Cancer 7, 278 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"53197_CR21","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.1007\/s00259-021-05672-x","volume":"49","author":"X Wang","year":"2022","unstructured":"Wang, X. et al. Preclinical and exploratory human studies of novel 68Ga-labeled D-peptide antagonist for PET imaging of TIGIT expression in cancers. Eur. J. Nucl. Med. Mol. Imaging 49, 2584\u20132594 (2022).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"53197_CR22","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1007\/s00259-023-06164-w","volume":"50","author":"IHC Miedema","year":"2023","unstructured":"Miedema, I. H. C. et al. 89Zr-immuno-PET using the anti-LAG-3 tracer [89Zr]Zr-BI 754111: demonstrating target specific binding in NSCLC and HNSCC. Eur. J. Nucl. Med. Mol. Imaging 50, 2068\u20132080 (2023).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"53197_CR23","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/d41573-019-00167-9","volume":"18","author":"J Xin Yu","year":"2019","unstructured":"Xin Yu, J., Hubbard-Lucey, V. M. & Tang, J. Immuno-oncology drug development goes global. Nat. Rev. Drug Discov. 18, 899\u2013900 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"53197_CR24","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1038\/s41591-022-02084-8","volume":"28","author":"L Kist de Ruijter","year":"2022","unstructured":"Kist de Ruijter, L. et al. Whole-body CD8+ T cell visualization before and during cancer immunotherapy: a phase 1\/2 trial. Nat. Med. 28, 2601\u20132610 (2022).","journal-title":"Nat. Med."},{"key":"53197_CR25","first-page":"720","volume":"63","author":"MD Farwell","year":"2022","unstructured":"Farwell, M. D. et al. CD8-targeted PET imaging of tumor-infiltrating T cells in patients with cancer: a phase I first-in-humans study of 89Zr-Df-IAB22M2C, a radiolabeled anti-CD8 minibody. J. Nucl. Med. 63, 720\u2013726 (2022).","journal-title":"J. Nucl. Med."},{"key":"53197_CR26","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/s41568-023-00560-y","volume":"23","author":"G Oliveira","year":"2023","unstructured":"Oliveira, G. & Wu, C. J. Dynamics and specificities of T cells in cancer immunotherapy. Nat. Rev. Cancer 23, 295\u2013316 (2023).","journal-title":"Nat. Rev. Cancer"},{"key":"53197_CR27","doi-asserted-by":"publisher","first-page":"e003543","DOI":"10.1136\/jitc-2021-003543","volume":"10","author":"C Lu","year":"2022","unstructured":"Lu, C. et al. G6PD functions as a metabolic checkpoint to regulate granzyme B expression in tumor-specific cytotoxic T lymphocytes. J. Immunother. Cancer 10, e003543 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"53197_CR28","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1158\/0008-5472.CAN-16-3346","volume":"77","author":"BM Larimer","year":"2017","unstructured":"Larimer, B. M. et al. Granzyme B PET imaging as a predictive biomarker of immunotherapy response. Cancer Res. 77, 2318\u20132327 (2017).","journal-title":"Cancer Res."},{"key":"53197_CR29","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1158\/1078-0432.CCR-18-2407","volume":"25","author":"BM Larimer","year":"2019","unstructured":"Larimer, B. M. et al. The effectiveness of checkpoint inhibitor combinations and administration timing can be measured by granzyme B PET imaging. Clin. Cancer Res. 25, 1196\u20131205 (2019).","journal-title":"Clin. Cancer Res."},{"key":"53197_CR30","doi-asserted-by":"publisher","DOI":"10.1172\/JCI161065","volume":"132","author":"H Zhou","year":"2022","unstructured":"Zhou, H. et al. Noninvasive interrogation of CD8+ T cell effector function for monitoring early tumor responses to immunotherapy. J. Clin. Invest. 132, e161065 (2022).","journal-title":"J. Clin. Invest."},{"key":"53197_CR31","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/s41586-018-0130-2","volume":"557","author":"Y Simoni","year":"2018","unstructured":"Simoni, Y. et al. Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates. Nature 557, 575\u2013579 (2018).","journal-title":"Nature"},{"key":"53197_CR32","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1021\/acs.jmedchem.0c01786","volume":"64","author":"P Bhutani","year":"2021","unstructured":"Bhutani, P. et al. U.S. FDA approved drugs from 2015-June 2020: a perspective. J. Med. Chem. 64, 2339\u20132381 (2021).","journal-title":"J. Med. Chem."},{"key":"53197_CR33","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","volume":"18","author":"J Galon","year":"2019","unstructured":"Galon, J. & Bruni, D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat. Rev. Drug Discov. 18, 197\u2013218 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"53197_CR34","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41571-018-0142-8","volume":"16","author":"JS O\u2019Donnell","year":"2019","unstructured":"O\u2019Donnell, J. S., Teng, M. W. L. & Smyth, M. J. Cancer immunoediting and resistance to T cell-based immunotherapy. Nat. Rev. Clin. Oncol. 16, 151\u2013167 (2019).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"53197_CR35","doi-asserted-by":"publisher","first-page":"55s","DOI":"10.2967\/jnumed.108.057240","volume":"50","author":"N Avril","year":"2009","unstructured":"Avril, N., Sassen, S. & Roylance, R. Response to therapy in breast cancer. J. Nucl. Med. 50, 55s\u201363s (2009).","journal-title":"J. Nucl. Med."},{"key":"53197_CR36","doi-asserted-by":"publisher","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","volume":"15","author":"JD Wolchok","year":"2009","unstructured":"Wolchok, J. D. et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin. Cancer Res. 15, 7412\u20137420 (2009).","journal-title":"Clin. Cancer Res."},{"key":"53197_CR37","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/s41422-020-0379-5","volume":"30","author":"JA Shyer","year":"2020","unstructured":"Shyer, J. A., Flavell, R. A. & Bailis, W. Metabolic signaling in T cells. Cell Res. 30, 649\u2013659 (2020).","journal-title":"Cell Res."},{"key":"53197_CR38","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1148\/radiol.210518","volume":"306","author":"L Dercle","year":"2023","unstructured":"Dercle, L. et al. Emerging and evolving concepts in cancer immunotherapy imaging. Radiology 306, 32\u201346 (2023).","journal-title":"Radiology"},{"key":"53197_CR39","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/s40425-019-0805-8","volume":"7","author":"S Das","year":"2019","unstructured":"Das, S. & Johnson, D. B. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J. Immunother. Cancer 7, 306 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"53197_CR40","doi-asserted-by":"publisher","first-page":"6710","DOI":"10.1182\/bloodadvances.2023010665","volume":"7","author":"JW de Boer","year":"2023","unstructured":"de Boer, J. W. et al. Inflammatory reactions mimic residual or recurrent lymphoma on [18F]FDG-PET\/CT after CD19-directed CAR T-cell therapy. Blood Adv. 7, 6710\u20136716 (2023).","journal-title":"Blood Adv."},{"key":"53197_CR41","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1038\/ni.2050","volume":"12","author":"J Thiery","year":"2011","unstructured":"Thiery, J. et al. Perforin pores in the endosomal membrane trigger the release of endocytosed granzyme B into the cytosol of target cells. Nat. Immunol. 12, 770\u2013777 (2011).","journal-title":"Nat. Immunol."},{"key":"53197_CR42","doi-asserted-by":"publisher","first-page":"28239","DOI":"10.1073\/pnas.2004570117","volume":"117","author":"XA Zhou","year":"2020","unstructured":"Zhou, X. A. et al. KLHL22 maintains PD-1 homeostasis and prevents excessive T cell suppression. Proc. Natl Acad. Sci. USA 117, 28239\u201328250 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"53197_CR43","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1056\/NEJMoa2302312","volume":"388","author":"RN Eskander","year":"2023","unstructured":"Eskander, R. N. et al. Pembrolizumab plus chemotherapy in advanced endometrial cancer. N. Engl. J. Med 388, 2159\u20132170 (2023).","journal-title":"N. Engl. J. Med"},{"key":"53197_CR44","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.2147\/DDDT.S136988","volume":"11","author":"RL Van Heertum","year":"2017","unstructured":"Van Heertum, R. L. et al. Lugano 2014 criteria for assessing FDG-PET\/CT in lymphoma: an operational approach for clinical trials. Drug Des. Devel Ther. 11, 1719\u20131728 (2017).","journal-title":"Drug Des. Devel Ther."},{"key":"53197_CR45","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan, S. et al. TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554, 544\u2013548 (2018).","journal-title":"Nature"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-53197-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-53197-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-53197-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T15:02:37Z","timestamp":1728572557000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-53197-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,10]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["53197"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-53197-2","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,10]]},"assertion":[{"value":"2 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Z.-F.L. and H.Z. are inventors of a granted patent entitled \u201cGranzyme B-targeting complex, radiopharmaceutical, preparation method therefor and use thereof\u201d (patent number, ZL202111370138.7) related to <sup>68<\/sup>Ga-grazytracer described in this study. Other authors declare no potential conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8791"}}